Compare Bristol-Myers Squibb Co (BMY) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals.
| BMY | FLRN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $30.86 |
52-Week Low | $42.60 | $30.65 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.80 with no recent price movement. The technical outlook is bearish with moving averages signaling caution, though RSI levels suggest potential oversold conditions. Recent institutional buying by Farther Finance Advisors and BCS Wealth Management indicates professional interest. The fund focuses on floating-rate investment grade bonds, positioning it as a potential hedge in the current rising rate environment.
FLRN offers exposure to floating-rate debt securities that may outperform in a rising rate environment. The fund's structure provides inflation protection benefits, but faces headwinds from potential credit quality deterioration and market volatility. Current dividend payments of $0.11 per share provide income support, though the bearish technical signals warrant careful monitoring of market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
